Andy Chen
Stock Analyst at Wolfe Research
(1.80)
# 3,066
Out of 4,843 analysts
34
Total ratings
33.33%
Success rate
-5.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $39.03 | +56.28% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $6.86 | +206.12% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $22.01 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $30.34 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $9.66 | - | 1 | Feb 4, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $20 | $10.82 | +84.93% | 1 | Feb 4, 2025 | |
| VERA Vera Therapeutics | Initiates: Outperform | $49 | $18.81 | +160.50% | 1 | Feb 4, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $19 | $9.63 | +97.30% | 1 | Feb 4, 2025 | |
| IMVT Immunovant | Downgrades: Peer Perform | n/a | $14.61 | - | 2 | Jan 3, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $697 | $570.17 | +22.24% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $299.70 | - | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $64.41 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $19.25 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $28.83 | +125.46% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $49.94 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $272.96 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.62 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $0.88 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $33.52 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $35.70 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $10.92 | +55.68% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $439.82 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $69.91 | -39.92% | 1 | Feb 15, 2024 |
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $39.03
Upside: +56.28%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $6.86
Upside: +206.12%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $22.01
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $30.34
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.66
Upside: -
Oruka Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $10.82
Upside: +84.93%
Vera Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $18.81
Upside: +160.50%
Zenas BioPharma
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $9.63
Upside: +97.30%
Immunovant
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $14.61
Upside: -
argenx SE
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $570.17
Upside: +22.24%
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $299.70
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $64.41
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $19.25
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $28.83
Upside: +125.46%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $49.94
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $272.96
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $13.62
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $0.88
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $33.52
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $35.70
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $10.92
Upside: +55.68%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $439.82
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $69.91
Upside: -39.92%